Feed ZTS
ZT

Zoetis

ZTS · NYSE

$73.41 -0.35% (-$0.26)
1M +0.96%
Market Cap $30.8B
P/E Ratio 11.76x
Div. Yield 2.85%
ROE 69.25%

Bulios Fair Price

$96.21

31.1% upside

Trenutna cena

$73.41

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica ZTS trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Strong
7/9
Valuation
75 /100
Cheap
PEG 1.53x
P/S 3.23x
P/B 9.78x
Growth
58 /100
Stable
Rev. growth 5.42%
FCF growth 19.85%
Book val. growth 8.89%
Profitability
100 /100
Strong
Net margin 27.49%
Op. margin 37.00%
FCF margin 24.86%
Quality
93 /100
Excellent
ROE 69.25%
ROA 17.35%
Asset turnover 0.63x
Debt
57 /100
Moderate
Current ratio 3.08x
Int. coverage 14.39x
Net debt/EBITDA 2.00x
Stability
100 /100
Stable
Rev. volatility 3.04%
EPS volatility 2.52%
Profitable years 6

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ZTS
Online

O podjetju

Zoetis Inc. (ZTS) is a global pharmaceutical company focused on animal health, headquartered in the USA. The company specializes in the development, manufacturing, and sale of medications and vaccines for animals. Zoetis provides a wide range of products for animal treatment and disease prevention in both domestic pets and livestock. Their portfolio includes medications for animals such as dogs, cats, cattle, pigs, poultry, and others. With its research, innovations, and global presence, Zoetis has gained a leading position in the field of animal health. The company focuses on improving the quality of life for animals and supports animal health worldwide. Zoetis Inc. (ZTS) shares can be an attractive investment opportunity for investors monitoring the animal health sector and valuing stability and long-term growth in this industry.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Kristin C. Peck

Employees

14,500

Headquarters

Parsippany

Prihajajoči dogodki

03 NOV.

Earnings

Upcoming earnings report

48d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.